This technical information note provides guidance to TB programme managers and quantification and procurement officers. The note includes information about the child-friendly DR-TB formulations and guidance on how to quantify and plan an order.
Favorite
2023
The resource provides recommendations for the programmatic management of tuberculosis preventive treatment. Modules of the WHO consolidated guidelines on tuberculosis are complemented by matching modules of the WHO operational handbook on tuberculosis.
Favorite
Civil Surgeons
Correctional Facility Staff
Government Agencies
Infection Control and Occupational Health Workers
International Agencies
Physicians
2020
The revised guidelines includes recommendations for specific administrative controls, environmental controls, and respiratory protection controls.
Favorite
Community Based Organizations
Health Educators/Communicators
Nurses
Physicians
2020
The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendations on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-susceptible TB...
Favorite
2019
The 2019 Maryland Department of Health Guidelines for Prevention and Treatment of Tuberculosis serves a resource for Maryland healthcare providers and local health departments. The guidelines were approved by TB experts and TB clinicians within Maryland.
Favorite
Physicians
Nurses
2019
Laboratory services, such as sputum specimen diagnosis, are vital to effective TB control. This resource may be used by laboratories to develop institutional policies that support proper collection and submission of sputum specimens for TB testing.
Favorite
Lab Personnel
2018
These new guidelines supersede previous WHO policy documents on the management of LTBI in people living with HIV, household contacts of people with active TB, other groups at risk of developing TB, and for LTBI testing. The consolidated guidelines are expected to provide the basis and rationale for the development of national guidelines for LTBI management, adapted to the national and local epidemiology of TB, the availability of resources, the health infrastructure and other national and local determinants...
Favorite
Civil Surgeons
Infection Control and Occupational Health Workers
International Agencies
Lab Personnel
2018
This document provides specific guidance for screening and post- screening management of all people who have been identified through public health investigations as having been exposed to multidrug resistant tuberculosis (MDR TB). Recommendations for symptomatic contacts, children less than 5 years of age and those who are highly immunocompromised (see step 1B) are different from other groups...
Favorite
Persons with TB
2018
The goal of this document is to provide practical answers to ethical questions in regard to the End TB Strategy.
Favorite
International Agencies
2017
These guidelines contain policy recommendations on priority areas in the treatment of drug-susceptible TB and patient care.
Favorite
2017
These guidelines aim to reduce morbidity and mortality related to TB and HIV-associated TB among people who inject drugs (PWID) through the integrated delivery of a comprehensive and holistic package of care. The guidelines provide an update of the 2008 Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach.
Favorite
2016
The purpose of this document is to provide guidance for clinicians, nurses, and hospital infection preventionists on the use of the Xpert MTB/RIF assay when making decisions to discontinue airborne infection isolation for persons with suspected, infectious pulmonary TB.
Favorite
Infection Control and Occupational Health Workers
2016
The WHO treatment guidelines for drug-resistant TB contains policy recommendations on priority areas in the treatment of drug-resistant TB.
Favorite
2016
This document describes the steps necessary to implement the shorter regimen and the new drugs for drug-resistant TB treatment, including diagnosis and bacterial confirmation of drug resistance, treatment regimen design, monitoring of treatment efficacy and safety, and programmatic evaluation.
Favorite
International Agencies
2016
This document presents guidance on the design and implementation of surveys and surveillance systems to measure the burden and trends of drug-resistant tuberculosis.
Favorite
International Agencies
2015
